-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Vb8TMoUxnc2xENw6FgEZDuyDhO2QuEIYrGED1ltx3YwuyTAvYhyX1AB/r4zmjCNu kIsq6XmiW4zUGAiiohHPyA== 0001209191-08-067477.txt : 20081229 0001209191-08-067477.hdr.sgml : 20081225 20081229131845 ACCESSION NUMBER: 0001209191-08-067477 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081223 FILED AS OF DATE: 20081229 DATE AS OF CHANGE: 20081229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DOWNEY BRUCE CENTRAL INDEX KEY: 0001237257 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09860 FILM NUMBER: 081271963 BUSINESS ADDRESS: STREET 1: BARR LABORATORIES INC STREET 2: 300 CORPORATE DRIVE SUITE 10 CITY: BLAUVELT STATE: NY ZIP: 10913 BUSINESS PHONE: 18002275227 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BARR PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000010081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221927534 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 BUSINESS PHONE: 201-930-3300 MAIL ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 FORMER COMPANY: FORMER CONFORMED NAME: BARR LABORATORIES INC DATE OF NAME CHANGE: 19920703 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2008-12-23 1 0000010081 BARR PHARMACEUTICALS INC BRL 0001237257 DOWNEY BRUCE BARR PHARMACEUTICALS, INC. 225 SUMMIT AVE MONTVALE NJ 07645 1 1 0 0 Chairman & CEO Common Stock 2008-12-23 4 D 0 426654 D 0 D Stock Options 11.06 2008-12-23 4 D 0 168729 D 2009-08-11 Common Stock 168729 0 D Stock Options 24.5667 2008-12-23 4 D 0 135000 D 2010-08-09 Common Stock 135000 0 D Stock Options 36.3267 2008-12-23 4 D 0 168749 D 2011-08-08 Common Stock 168749 0 D Stock Options 26.58 2008-12-23 4 D 0 191220 D 2012-08-07 Common Stock 191220 0 D Stock Options 43.34 2008-12-23 4 D 0 149998 D 2013-07-30 Common Stock 149998 0 D Stock Options 35.01 2008-12-23 4 D 0 160000 D 2014-08-04 Common Stock 160000 0 D Stock Appreciation Rights 46.99 2008-12-23 4 D 0 160000 D 2015-07-27 Common Stock 160000 0 D Stock Appreciation Rights 48.80 2008-12-23 4 D 0 150000 D 2016-07-26 Common Stock 150000 0 D Stock Appreciation Rights 49.49 2008-12-23 4 D 0 75000 D 2008-11-11 2017-03-07 Common Stock 75000 0 D Stock Appreciation Rights 49.22 2008-12-23 4 D 0 150000 D 2008-11-11 2018-03-04 Common Stock 150000 0 D Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 265,716 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $16,903,823. Option vested equally over a 3 year period from grant date These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $9,354,335.76, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $11.06 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $5,660,995.50, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $24.5667 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $5,091,714.20, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $36.3267 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $7,633,502.40, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $26.58 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $3,473,953.68, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $5,038,400.00, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $3,121,600.00, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $2,655,000.00, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,275,750.00, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $2,592,00.00, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share. /s/ William T. McKee as Attorney-in-Fact for Bruce Downey 2008-12-29 -----END PRIVACY-ENHANCED MESSAGE-----